# CIPLA: Generic drug approval for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | CIPLA |
| Product | FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE |
| Generic / ingredient | FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE |
| Approval | Generic drug approval (ANDA) |
| Application | ANDA213087 |
| Decided | 2026-07-27 |
| Panel / class | POWDER, INHALATION |

## Why this score
- A generic launch.

Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213087). Last refreshed: 2026-11-04T06:06:18.796Z.
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.